PharmaBoardroom

Gabriel O’Shea, National Commissioner of Seguro Popular, on how the institute generates more efficient and transparent resource allocation across…

The following chart gives the key statistics on the Italian pharmaceutical industry; from number of manufacturing plants, to investments and export…

Francisco González, CEO of ProMéxico, the Mexican investment agency, describes the strengths of Mexico’s research and industrial base, untapped…

Professor Dr. Susan M. Gasser of the Friedrich Miescher Institute for Biomedical Research describes FMI’s fundamental connection between academia…

Pfizer Switzerland’s Pamela Alexa discusses launching Xeljanz (tofacitinib), a treatment for adult patients with moderate to severe active…

Javier Amtmann, the new president of AMIIF, the Mexican association of pharmaceutical innovators, reveals AMIIF’s strategic priorities and key areas…

Known as “Ireland’s university of Enterprise,” Dublin City University’s research and educational philosophy is very much informed by the…

Switzerland’s pharma industry is moving beyond staid conservatism and embracing risk in order to compete internationally and foster a new culture of…

Gilles Pacaud and Christophe Bourillon discuss the importance of life sciences to Rockwell Automation France, industry trends and how the company…

Patricia Ostrosky, general director of the Institute of Biomedical Research in Mexico, details current research subjects and calls for greater…

Sandoz’s ambitious strategy in Mexico includes aggressive product launches in biosimilars and oncology, a heightened focus on the institutional…

Tackling both obesity and diabetes is a primary objective of the National Academy of Medicine of Mexico and requires a holistic, multidisciplinary…